<a href="https://www.medchemexpress.com/ARV-771.html">ARV-771</a>產(chǎn)品描述:ARV-771 is a potent bromodomain and extra-terminal (<b>BET</b>) proteins degrader with <b>K<sub>d</sub></b> values of 4.7, 7.6, 7.6 nM against bromodomain 2, 3 and 4, respectively. IC50 & Target: Kd: 4.7 (BRD 2), 7.6 (BRD 3), 7.6 nM (BRD 4)<sup>[1]</sup> IC50: less than 1 nM (c-MYC protein)<sup>[1]</sup> <i><b>In Vitro:</b></i> ARV-771 potently degrades BRD2/3/4 in 22Rv1 cells with a DC<sub>50</sub> less than 5 nM. c-MYC protein is a downstream effector of BET proteins. Treatment with ARV-771 results in depletion of c-MYC with an IC<sub>50</sub> of less than 1 nM. ARV-771 shows strong antiproliferative effect on 22Rv1, VCaP, and LnCaP95 cell lines. ARV-771 treatment has a pronounced effect on cell morphology consistent with apoptosis. FL-AR and AR-V7 mRNA are down-regulated upon treatment with 10 nM ARV-771 in VCaP cells. ARV-771 has an antiandrogenic effect on a number of AR-regulated genes in VCaP cells<sup>[1]</sup>. <i><b>In Vivo:</b></i> Treatment of non castrated male Nu/N<br><br> <br> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網(wǎng)點遍及全球20多個國家地區(qū)。MCE經(jīng)過多年努力已成為全球生物活性小分子領域的一流供應商, 產(chǎn)品涵蓋癌癥、神經(jīng)科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產(chǎn)品都進行嚴格的LCMS和NMR檢驗,其產(chǎn)品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時內送達客戶;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產(chǎn)品提供免費試用裝;</span> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);"> 已為全球多個知名企業(yè)、院校構建各種定制型化合物庫。</span><br><br>產(chǎn)品鏈接:<a href="http://www.medchemexpress.cn/arv-771.html">www.medchemexpress.cn/arv-771.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
ARV-771研究進展
發(fā)布日期:2017-10-27 瀏覽次數(shù):0
核心提示:a href=https://www.medchemexpress.com/ARV-771.htmlARV-771/a產(chǎn)品描述:ARV-771 is a potent bromodomain and extra-terminal
- 下一篇:暫無
- 上一篇:Olcegepant (hydrochloride)研究進展
行業(yè)動態(tài)
更多...
- ARV-771研究進展 10-27
- Olcegepant (hydrochlorid 10-27
- Beaucage reagent研究進展 10-27
- Olcegepant研究進展 10-27
- EC330研究進展 10-27
- CEP-40783研究進展 10-27
- Conduritol B epoxide研究 10-27
- CDD3506研究進展 10-27
- CDD3505研究進展 10-27
- ML364研究進展 10-27